Updated AAN Position Statement Issued on Seizures, Driving Licensure
By Elana Gotkine HealthDay Reporter
FRIDAY, March 28, 2025 -- In a position statement issued by the American Academy of Neurology and published online March 12 in Neurology, an updated consensus is presented relating to seizures, driving licensure, and medical reporting.
Benjamin Tolchin, M.D., from the Yale School of Medicine in New Haven, Connecticut, and colleagues reviewed the evidence relating to driving safety in the setting of seizures and developed a revised position statement to update those published in 1994 and 2007.
The authors present key consensus positions, including national driving standards promulgated through a system such as the Uniform Law Commission, which would reduce confusion and improve adherence with state driving standards in the United States, as well as promulgation of state licensing criteria for medical conditions by regulations and guidelines based on enabling legislation rather than in statutes, with development by medical advisory boards working with departments of motor vehicles. Licensing criteria should be equitable, nondiscriminatory, objective, and compatible with similar risks in other populations. In all cases, a minimum seizure-free interval of three months should usually be required before driving based on review of favorable and unfavorable features; this interval can be extended by medical advisory boards in individual cases. A seizure-free interval may not be required before resuming driving for individuals with exclusively provoked seizures attributable to provoking factors that are unlikely to recur. Driving should be paused during tapering and following discontinuation of an antiseizure medication if another such medication is not introduced. Health care practitioners should be allowed but not mandated to report drivers posing elevated risk.
"This position statement aims to improve the management of this complex personal, medical, governmental, and societal issue," Tolchin said in a statement.
Two authors disclosed ties to the pharmaceutical and biotechnology industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Parent-Reported Firearm Storage Poor Estimator of Teen Perceived Access
MONDAY, June 16, 2025 -- Parent-reported firearm storage seems to be a poor estimator of teen perceived firearm access, according to a study published online June 10 in JAMA...
CT Colonography Cost-Effective, Clinically Effective for CRC Screening
MONDAY, June 16, 2025 -- Computed tomography colonography (CTC) is cost-effective and clinically effective for colorectal cancer (CRC) screening, according to a study published...
Global Incidence Rate of Rheumatoid Arthritis Increased From 1990 to 2021
MONDAY, June 16, 2025 -- The incidence rate of rheumatoid arthritis (RA) increased globally from 1990 to 2021, with the heaviest burden born by regions with a high...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.